<?xml version="1.0" encoding="UTF-8"?>
<results title="test_trace">
 <result pre="not comply with these terms. Abstract Hepatitis C virus (HCV)" exact="infection" post="is one of the most serious complications of transfusion"/>
 <result pre="disease (SCD) population before 1990; in fact, since 1990 serological" exact="tests" post="were made available to detect infection in blood donors."/>
 <result pre="fact, since 1990 serological tests were made available to detect" exact="infection" post="in blood donors. The iron chelation therapy has improved"/>
 <result pre="in liver disease due to the iron overload and HCV" exact="infection" post="that lead to liver fibrosis, cirrhosis, and hepatocellular carcinoma."/>
 <result pre="carcinoma. Until few years ago, the recommended therapy for HCV" exact="treatment" post="consisted of pegylated-interferon alpha plus ribavirin, a therapy with"/>
 <result pre="alpha plus ribavirin, a therapy with important side effects. This" exact="treatment" post="has been severely limited to thalassemic and SCD patients"/>
 <result pre="for the high costs of the new drugs. Recently, all" exact="treatment" post="regimens can be used for patients with various HCV"/>
 <result pre="table-count: equation-count: ref-count: page-count: word-count: Introduction Hepatitis C virus (HCV)" exact="infection" post="is one of the most serious complications of transfusion"/>
 <result pre="transfusions before 1990; in fact, since the year 1990 serological" exact="tests" post="were made available for detect infections in blood donors."/>
 <result pre="al., 2004; Agas et al., 2008). Iron overload and HCV" exact="infection" post="have been established to be risk factors for thalassemia"/>
 <result pre="2019). Only 15–25% of the infected subjects can eliminate the" exact="infection" post="alone. The remaining 75–85% of them make the infection"/>
 <result pre="the infection alone. The remaining 75–85% of them make the" exact="infection" post="chronic, developing cirrhosis that can be complicated by liver"/>
 <result pre="population of thalassemic patients (United States, Italy and Greece) the" exact="prevalence" post="of cirrhosis ranged from 10 to 20% and the"/>
 <result pre="2019). These data have made an intervention to eradicate HCV" exact="infection" post="more urgent. Regarding Sickle Cell Anemia, about 10–20% of"/>
 <result pre="manage the sickling crisis and anemia, patients affected by HCV" exact="infection" post="frequently are exposed to higher risk of iron overload"/>
 <result pre="informed consent to participate in this study. Effectiveness of the" exact="treatment" post="according to the clinical case, was compared to HCV"/>
 <result pre="the life expectancy of the patients. HCV Therapy: Interferon The" exact="treatment" post="of chronic HCV infection began with the administration of"/>
 <result pre="the patients. HCV Therapy: Interferon The treatment of chronic HCV" exact="infection" post="began with the administration of interferon (INF) mono therapy,"/>
 <result pre="a few years ago the recommended therapy available for HCV" exact="treatment" post="was pegylated-interferon (PEG-IFN) alpha, plus ribavirin (RBV) with an"/>
 <result pre="et al., 2016a,b, 2017, 2018; Catauro et al., 2018). This" exact="treatment" post="produced important side effects, such as irritation at the"/>
 <result pre="mental disorders, thyropathy, neutropenia, and hemolytic anemia. Eradication of the" exact="infection" post="did not reach the expected results, due to the"/>
 <result pre="SVR rates of 25–64% in patients with thalassemia and HCV" exact="infection" post="(Inati et al., 2005; Harmatz et al., 2008; Di"/>
 <result pre="cirrhosis and hepatocellular carcinoma (Ray and Thomas, 2015). However, this" exact="treatment" post="was not well-tolerated by thalassemic and SCD patients and"/>
 <result pre="2011 the development of DAAs gave a breakthrough to the" exact="treatment" post="of patients with chronic HCV. The therapy with DAAs"/>
 <result pre="few studies focused on safety, tolerability and efficacy of LDV/SOF" exact="treatment" post="for patients with SCD (Moon et al., 2017). The"/>
 <result pre="thalassemia intermedia, and sickle cell disease patients with chronic HCV" exact="infection" post="and fibrosis stage of F3–F4 were enrolled and then"/>
 <result pre="of at least 10 KPa. Thirty-four patients with a confirmed" exact="diagnosis" post="of hemoglobinopathy and HCV infection were treated with DAAs"/>
 <result pre="Thirty-four patients with a confirmed diagnosis of hemoglobinopathy and HCV" exact="infection" post="were treated with DAAs in the period 2015–2018. The"/>
 <result pre="concentration (LIC), and serum ferritin values between baseline and after" exact="treatment" post="at the SVR evaluation. Patients, n 34 Age, years"/>
 <result pre="the patients had previously treated with Interferon to eradicate HCV" exact="infection" post="but were not responsive to the therapy. The HCV"/>
 <result pre="between 10.0 and 34.8 KPa. Some comorbidities were present before" exact="treatment" post="in the group of patients. Five thalassemia major subjects"/>
 <result pre="Table 2. Table 2 DAAs therapies and virological response after" exact="treatment" post="regimens. DAAs therapy, n (%) Sofosbivir + Ledipasvir 14"/>
 <result pre="n(%) Sustained Virological Response (SVR) 32/34 (94%) Not responder with" exact="infection" post="relapse 2/34 (6%) All patients were treated with a"/>
 <result pre="comorbidities and treated for 24 weeks, were not responder with" exact="infection" post="relapse after 1 month. One of them had hepatocellular"/>
 <result pre="12 weeks DAAs therapy without viral recurrence. Already before the" exact="treatment" post="the patient had significant hepatic impairment with a high"/>
 <result pre="the patient did not have a primary sclerosing cholangitis. All" exact="treatment" post="regimens were well-tolerated, and no adverse events were reported."/>
 <result pre="events were reported. No patient has modified the ongoing iron-chelation" exact="treatment" post="and the number of blood transfusions remained unchanged. The"/>
 <result pre="remained unchanged. The evaluation of some parameters before and after" exact="treatment" post="(Table 1) suggested a significant reduction (p = 0.018)"/>
 <result pre="other hand, the liver iron concentration (LIC) resulted decreased after" exact="treatment" post="from 1.85 ± 1.22 to 1.66 ± 0.72 mgFe/g"/>
 <result pre="available in the literature suggest that the eradication of HVC" exact="infection" post="using the new DAAs is very close. In addition,"/>
 <result pre="comorbidities when were treated, as in our non-responder subjects with" exact="infection" post="relapse after 1 month. Moreover, at first the treatment"/>
 <result pre="with infection relapse after 1 month. Moreover, at first the" exact="treatment" post="of patients did not include new types of DAAs"/>
 <result pre="the big problem of the costs of DAAs therapies. These" exact="treatment" post="regimens are very expensive, the costs can vary according"/>
 <result pre="and efficacy of adding ribavirin to interferon or peginterferon in" exact="treatment" post="of hepatitis C infection in patients with thalassemia: a"/>
 <result pre="ribavirin to interferon or peginterferon in treatment of hepatitis C" exact="infection" post="in patients with thalassemia: a systematic review on randomized"/>
 <result pre="69, 1066–1070. 10.1136/jech-2014-20507525922472 DharamsiS. R.SwaminathanM.VenkatakrishnanL.KrishnaveniJ.MohandasN.VegirajuV.et al. (2017). Direct acting antiviral" exact="treatment" post="response in chronic hepatitis C infection: data from tertiary"/>
 <result pre="and efficacy of pegylated interferon alpha-2a and ribavirin for the" exact="treatment" post="of hepatitis C in patients with thalassemia. Haematologica93, 1247–1251."/>
 <result pre="K.ChanP. K.LingS. C.HaS. Y. (2002). Interferon and ribavirin as frontline" exact="treatment" post="for chronic hepatitis C infection in thalassaemia major. Br."/>
 <result pre="Interferon and ribavirin as frontline treatment for chronic hepatitis C" exact="infection" post="in thalassaemia major. Br. J. Haematol. 117, 755–758. 10.1046/j.1365-2141.2002.03491.x12028054"/>
 <result pre="and efficacy of sofosbuvir and daclatasvir for hepatitis C virus" exact="infection" post="in patients with β-thalassemia major. J. Clin. Exp. Hepatol."/>
 <result pre="G.et al.. (2017). Efficacy and safety of Ledipasvir/Sofosbuvir for the" exact="treatment" post="of chronic hepatitis C in persons with sickle cell"/>
 <result pre="NagralA.SawantS.MaldeP.ParikhP.NagralN.MerchantR. (2017). Experience with direct acting antivirals (DAA) agents in" exact="treatment" post="of chronic hepatitis C virus (HCV) infection in patients"/>
 <result pre="(DAA) agents in treatment of chronic hepatitis C virus (HCV)" exact="infection" post="in patients of thalassemia major. J. Clin. Exp. Hepatol."/>
 <result pre="172–178. 10.1016/j.jceh.2017.08.00228970702 OrigaR.MarcedduG.DanjouF.PerseuL.SattaS.DemartisF. R.et al.. (2015). IFNL3 polymorphisms and HCV" exact="infection" post="in patients with beta thalassemia. Ann. Hepatol. 14, 389–395."/>
 <result pre="L.FilosaA.Galeota LanzaA.PigaA.SaraccoG. M.et al.. (2017). Treatment of hepathitis C virus" exact="infection" post="with direct-acting antiviral drugs is safe and effective in"/>
 <result pre="39–72. 10.1080/05704928.2016.1207658 RisolutiR.GregoriA.SchiavoneS.MaterazziS. (2018). Click and screen technology for the" exact="detection" post="of explosives on human hands by a portable MicroNIR-chemometrics"/>
</results>
